LONDON, Nov. 23, 2015 /PRNewswire/ -- This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Modern healthcare infrastructure, increasing sedentary lifestyle in young population and rising obese population are expected to propel the global hypertrophic cardiomyopathy therapeutics market.
The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.
Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been segmented into four major categories: Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Antiarrhythmic Agents, and Anticoagulants. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global hypertrophic cardiomyopathy therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, India, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East, Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global hypertrophic cardiomyopathy therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG
The global hypertrophic cardiomyopathy therapeutics market is segmented as follows:
Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class
Beta Adrenergic Blocking Agents
Calcium Channel Blockers
Global Hypertrophic Cardiomyopathy Therapeutics, by Geography
Rest of Europe
Rest of Asia Pacific
Rest of the World
Download the full report: https://www.reportbuyer.com/product/3411213/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers